Team

Ferran Prat

Chairman of the Board of Directors

He holds more than 30 years of experience in the Life Science industry mainly in Diagnostics and Pharmaceutical. He has served as CEO, Corporate Vice President of Marketing, Strategic Alliances and Business Development as well as Chief Commercial Officer and Chief Operations Officer in several companies such as VITRO Group, Werfen, LETI Pharma, DAKO (an Agilent Technologies company) where he has had global responsibility across the whole value chain mainly in headquarters, but also for EMEAI, Americas and Asia Pacific regions where he has been based.
Ferran holds a B.Sc. in Pharmacy from the University of Barcelona, a Master in marketing management from EADA (Barcelona, Spain) and a Master in Digital Transformation from IESE (Barcelona Spain).

Marta Barrachina

CEO
CO-FOUNDER
Member of the Board of Directors

Marta Barrachina is PhD in Biochemistry (University of Barcelona) and Executive MBA (La Salle-Ramon Llull University). She was a principal investigator at the Bellvitge Biomedical Research Institute for 17 years. Author of several scientific articles published in international journals related to neurodegenerative diseases, and inventor of 9 patents. She is Member of the Scientific Review Board at Alzheimer’s Drug Discovery Foundation (ADDF) since January 2021. CEO of the company since its inception at the end of 2017.

Santiago Lozano

Member of the Board of Directors

Bachelor in Economics (University of Navarra, 1996) and Master's in Financial Management (ESIC, 2004). He is a collaborator of the Master of Biomedical Engineering at the University of Navarra and various international organizations for the evaluation of innovative projects in early stages, especially in the health sector. He has accumulated nearly 25 years of professional experience, initially in the industrial sector (automotive at ICER Brakes) and later in the financial sector (capital markets at Gesnavarra SGIIC), and for more than 15 years he has been involved in Venture Capital and Technology Transfer as Fund Director at Clave Capital. He has promoted various technology transfer funds and analyzed and invested in early-stage technology companies, particularly in the fields of health and engineering. Currently, he is also a member of 15 boards of directors and the director of UN I+D+i Tech Transfer F.C.R. and Navarra Tech Transfer Fund F.C.R., specializing mainly in health and engineering.

Maite Fibla

Member of the Board of Directors

Maite Fibla is PhD in Economics and Co-Founder & Managing Partner at Ship2B Ventures, an impact Venture Capital firm born in late 2020 that manages more than €50MM and invests in startups with high social and environmental impact. In 2013 she also co-founded the Ship2B Foundation which aims to boost the impact economy. The foundation has accelerated more than 200 startups and has invested in several high-impact startups.

Howard Fillit

ADDF Observer of the Board of Directors

Howard Fillit is a geriatrician, neuroscientist, and leading expert in Alzheimer’s disease and related dementias with many awards and honors including the Rita Hayworth Award from the Alzheimer's Association. He serves as the Co-Founder, Founding Executive Director, and Chief Science Officer of the Alzheimer's Drug Discovery Foundation (ADDF), a nonprofit organization that he helped establish in 1998. He is a fellow of the American Geriatrics Society, the American College of Physicians, the Gerontological Society of America, and the New York Academy of Medicine.

Russell Swerdlow

Scientific Advisor

Director of the University of Kansas Alzheimer’s Disease Research Center and the Heartland Center for Mitochondrial Medicine. He received undergraduate and MD degrees from New York University and trained as a neurologist and Alzheimer’s specialist at the University of Virginia. He holds the Gene and Marge Sweeney Chair at the University of Kansas and is a recipient of an S. Weir Mitchell Award from the American Academy of Neurology, a Cotzias Award from the American Parkinson’s Disease Association, a Chancellor’s Club Research Award from the University of Kansas, a Dolph Simons Research Achievement Award in the Biomedical Sciences from the University of Kansas, and the Oskar Fischer Prize. From 2017-2021 he sat on the NIA Board of Scientific Counselors. Dr. Swerdlow’s research focuses on brain energy metabolism, its role in Alzheimer’s disease, and its therapeutic manipulation.

Courosh Mehanian

Scientific Advisor

Research Associate Professor, Affiliate Faculty
Knight Campus for Accelerating Scientific Impact, University of Oregon
Eugene, Oregon, USA

Research Associate Professor, Affiliate Faculty
Oregon Health and Science University
Portland, Oregon, USA

Principal Research Scientist, Machine Learning
Global Health Labs
Bellevue, Washington, USA

Carlos Cruchaga

Scientific Advisor

Carlos Cruchaga, Ph.D., is a human genomicist with expertise in multiomics, informatics, and neurodegeneration. He completed his Ph.D. in Biochemistry and Molecular Biology in 2005 at University of Navarra in Spain. During his first post-doctoral he conducted statistical human genetics studies focused on Alzheimer’s disease and Parkinson’s disease, completing his training in quantitative human genomics. Dr. Cruchaga established his laboratory at Washington University in 2011, studying the genetic architecture of neurodegenerative diseases. His interests are focused in using human genomic and other omic data (proteomic, metabolomics, lipidomics) to identify and understand the biological process involved on Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia and other neurodegenerative processes. In 2019, he became the leader of the NeuroGenomics and Informatics group at Washington University.

Jordi Gascón

Medical Advisor
CO-FOUNDER

Jordi Gascón is the current Head of the Functional Dementia Unit at Bellvitge University Hospital and Associate Professor in Morphological Sciences at the Autonomous University of Barcelona. His expertise in the management and treatment of mild cognitive impairment and dementias (such as Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia, and amyotrophic lateral sclerosis with cognitive or behavioral impairment) has made him a reference consultant at his hospital and allowed him to collaborate with several pharmaceutical companies in many clinical trials.

Ramón Reñé

Medical Advisor
CO-FOUNDER

Ramon Reñé has been the Head of the Functional Dementia Unit at Bellvitge University Hospital until his retirement. His large experience in the treatment of patients with mild cognitive impairment, vascular dementia, frontotemporal degeneration, and dementia with Lewy bodies has allowed him to lead more than a dozen clinical trials in collaboration with leading pharmaceutical companies, such as Grifols, Lundbeck, Astra Zeneca, Eli Lilly, Biogen, and Roche. Moreover, he has also been focused on caregivers, maintaining close ties with Alzheimer’s familiar Associations.

Lidia Casas

Patent Attorney

Lídia is Qualified European Patent Attorney (EQE-2014) and has a degree in Biochemistry. She is a professional with 19 years experience in Intellectual Property, especially in the fields of biotechnology, biomedicine and medtech. She created her own project of patent consultancy particularly for start-up companies, Patent Riders. Lídia works for ADmit Therapeutics as external IP Manager, managing all the aspects of IP of the company.